Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / LLY - Nektar regains rights to atopic dermatitis candidate from Eli Lilly

LLY - Nektar regains rights to atopic dermatitis candidate from Eli Lilly

Eli Lilly and Company

2023-04-27 10:14:00 ET

  • Eli Lilly ( LLY ) is returning the rights to atopic dermatitis candidate rezpegaldesleukin (REZPEG) back to Nektar Therapeutics ( NASDAQ: NKTR ).
  • Earlier in April, Nektar ( NKTR ) said it would move REZPEG forward this year in a phase 2 trial for mild-to-severe atopic dermatitis.
  • Phase 1 data presented by Lilly ( LLY ) before indicated REZPEG showed dose-dependent improvemen t over placebo for key efficacy measures.
  • Seeking Alpha's Quant Rating has rated Nektar ( NKTR ) a strong sell since Feb. 16.

For further details see:

Nektar regains rights to atopic dermatitis candidate from Eli Lilly
Stock Information
Company Name: Eli Lilly and Company
Stock Symbol: LLY
Market: NYSE
Website: lilly.com
Menu
LLY LLY Quote LLY Short LLY News LLY Articles LLY Message Board
Get LLY Alerts

News, Short Squeeze, Breakout and More Instantly...